New drug aims to ease Opioid-Related constipation
NCT ID NCT01401985
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tested a drug called TD-1211 in 95 people who had constipation from taking opioid pain medications. The main goal was to see if the drug was safe and tolerable. Researchers also looked at whether it increased the number of complete and spontaneous bowel movements.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TD-1211
What this could lead to
If it works, this could lead to a new treatment option for constipation caused by opioid pain medications.
What could go wrong
This is an early pilot study with only 95 people, so results may not apply to everyone. The drug might not work better than a placebo or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPIOID INDUCED CONSTIPATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Theravance Biopharma Investigational Site
Pasadena, California, 91105, United States